| May 1, 2024 | Bluejay Therapeutics | $180.0M Series C | Daniel Estes | Eric Shiozaki, Digitalis Ventures, Frazier Healthcare Partners, RiverVest, Westlake Village BioPartners, Arkin Bio Ventures, HBM Healthcare Investments, Novo Holdings, RA Capital Management, RiverVest Venture Partners, T. Rowe Price Associates, Unicorn Capital, Wellington Management |
| Apr 12, 2024 | Century Therapeutics | $60.0M Other Equity | Adage Capital Management, Bain Capital Life Sciences, Octagon Capital, Superstring Capital | Boxer Capital, Casdin Capital, Dafna Capital, Venrock |
| Feb 13, 2024 | ProfoundBio | $112.0M Series B | Andrew Lam | Janus Henderson Investors, LifeSci Venture Partners, Josh Jin, Logos Capital, LYFE Capital, Medicxi, Nextech Invest, OrbiMed, Piper Heartland Healthcare Capital, RA Capital Management, Surveyor Capital, T. Rowe Price Associates |
| Mar 27, 2023 | ArriVent Biopharma | $155.0M Series B | Elena Viboch, James Healy | AIHC Capital, Catalio Capital Management, HBM Healthcare Investments, Hongshan Capital Group (Sequoia Capital China), Infinitum Asset Management, Lilly Asia Ventures, Carl Gordon, Shanghai Healthcare Capital, Sirona Capital, Terra Magnum Capital Partners, Unicorn Capital, Zoo Capital |
| Mar 1, 2023 | Allorion Therapeutics | $50.0M Series B | INCE Capital, Chen Kan | Amino Capital, Sue Xu, 3SBio, LongRiver Investments, Wei Cheng |
| Aug 1, 2022 | Bluejay Therapeutics | $41.0M Series B | Alon Lazarus In remembrance | Digitalis Ventures, RiverVest, InnoPinnacle Fund, Ting Jia (TJ), Nancy Hong, Bill Rutter, Yonjin Capital |
| Dec 14, 2021 | AnHeart Therapeutics | $61.0M Series B | Ting Jia (TJ) | Cenova Capital, Innovent Biologics, Laurion Capital Management, Sage Partners |
| Nov 24, 2021 | Allorion Therapeutics | $40.0M Series A | Qiming Venture Partners | IDG Capital, Med-Fine Capital, TF Capital |
| Jun 30, 2021 | ArriVent Biopharma | $150.0M Series A | Hillhouse Capital Group | Lilly Asia Ventures, Lyra Capital, OrbiMed, Zoo Capital |
| May 18, 2021 | Vedere Bio ll | $77.0M Series A | Ting Jia (TJ) | Atlas Venture, Casdin Capital, Benjamin Yerxa, Mission BioCapital, Samsara BioCapital |
| May 1, 2021 | NiKang Therapeutics | $200.0M Series C | Cormorant Asset Management, HBM Healthcare Investments, Ting Jia (TJ) | RTW Investments, Ally Bridge Group, BlackRock, Casdin Capital, CBC Group, EcoR1 Capital, Invus, Janus Henderson Investors, Lilly Asia Ventures, Logos Capital, Matrix Partners China, Zhenhai Gao, Pavilion Capital, Perceptive Advisors, PFM Health Sciences, RA Capital Management, Samsara BioCapital, Surveyor Capital, Wellington Management |
| May 1, 2021 | Affinia Therapeutics | $110.0M Series B | Caroline Stout, Farallon Capital Management | Atlas Venture, F-Prime Capital Partners, Ed Mathers, New Enterprise Associates, Avidity Partners, Casdin Capital, F-Prime Capital, Google Ventures, Lonza, Mass General Brigham Ventures, Perceptive Advisors, RA Capital Management, TCGX, Woodline Partners |
| May 1, 2021 | Numab | $110.0M Series C | Matthias Fehr, Nanna Lüneborg | 5AM Ventures, Forbion, F-Prime Capital Partners, Soffinova Partners, BlackRock, BVF Partners, Bihua Chen, RTW Investments |
| May 1, 2021 | Hummingbird Bioscience | $130.0M Series C | Ken Harrison | Frazier Healthcare Partners, Affinity Asset Advisors, Ally Bridge Group, Altrium Capital Management, Amgen Ventures, Droia Ventures, EDBI, Heritas Capital, Mirae Asset, Morningside Ventures, Polaris Partners, Pureos Bioventures, Kiel Kim |
| Apr 5, 2021 | Bioheng | $80.0M Series B | Decheng Capital, Octagon Capital | BlueRun Ventures China, Shenzhen Capital Group |
| Apr 1, 2021 | Forge Biologics | $120.0M Series B | Matthew Hammond | Perceptive Advisors, Drive Capital, Marshall Wace, Surveyor Capital |
| Mar 30, 2021 | Immune-Onc Therapeutics | $73.0M Onc Therapeutics - Series B | Dave Chenn | Northern Light Venture Capital, Sphera Healthcare, The Leukemia & Lymphoma Society, Vivo Capital |
| Mar 15, 2021 | Hanyu Medical | $76.9M Series D | Xiao (Albert) Huang | — |
| Mar 1, 2021 | Arctic Vision | $100.0M Series B | Roy Xie | CVentures, Adrian Cheng, Morningside Ventures, Nan Fung Life Sciences, Pivotal bioVenture Partners China, Tencent |
| Mar 1, 2021 | StrideBio | $82.0M Series B | Northpond Ventures, Novo Ventures | Advanced Technology Ventures, RA Capital, Venrock, Alexandria Venture Investments, CaaS Capital Management, Hatteras Venture Partners, Pontifax, Sarepta Therapeutics, Takeda Ventures, UCB Ventures, UF Innovate Ventures |
| Mar 1, 2021 | EpimAb Biotherapeutics | $120.0M Series C | Tony Rong, Sungwon Song | CVentures, Adrian Cheng, Cormorant Asset Management, Decheng Capital, Hidragon Capital, Hony Capital, SDIC Fund, ShangBay Capital, Sherpa Healthcare Partners, Yanchuang Capital |
| Mar 1, 2021 | Century Therapeutics | $160.0M Series C | Casdin Capital | Versant Ventures, Qatar Investment Authority, Marshall Wace, OrbiMed, RA Capital Management, Avidity Partners, Federated Kaufmann Fund, Fidelity Management & Research Company, Leaps by Bayer, Logos Capital |
| Feb 1, 2021 | Cullgen | $50.0M Series B | 3E Bioventures Capital | Heights Capital Management, MSA Capital |
| Jan 1, 2021 | Vera Therapeutics | $80.0M Series C | Abingworth | Amzak Health Investors, Avoro Ventures, Canaan Partners, General Catalyst, GV, Ali Behbahani, Osage University Partners, Sofinnova Investments, SR One, Westlake Village BioPartners, Alexandria Venture Investments, Fidelity Management & Research Company, Beth Seidenberg, Patrick Enright, Surveyor Capital |
| Sep 1, 2020 | NiKang Therapeutics | $50.0M Series B | RTW Investments | Casdin Capital, HBM Healthcare Investments, Lilly Asia Ventures, Matrix Partners China |
